The second strategy uses BRAF (V-Raf murine sarcoma viral oncogene homolog B1) and MEK (Mitogen-activated protein kinase kinase) inhibitors to block the mitogen-associated protein kinase (MAPK) pathway that is constitutively activated by BRAF V600 mutations in 45% of melanoma patients [5,7]. This evidence concerns the gene BRAF and melanoma.